ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
US stocks today: S&P 500, Nasdaq end higher, notch weekly gains after earnings-heavy week
The S&P 500 and Nasdaq reached record highs, fueled by strong earnings and falling crude prices, marking their longest weekly gain streak since October 2024.